Company intelligence / Profile preview

Gelmetix

Manchester, England, United Kingdomgelmetix.com ↗

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Gelmetix’s lead product DXM has completed successful preclinical studies and received regulatory approval in France to begin first-in-human clinical trials. The company’s technology has shown promise in rehydrating and stabilizing damaged spinal discs, with the goal of providing a minimally invasive alternative to surgery or chronic pain management. Clinical results from pilot studies suggest potential efficacy in restoring function and relieving pain in patients with degenerative disc disease.

Therapeutic areas: Rheumatology
Modalities: Hydrogel-based drug delivery therapyDevicePolymer-drug conjugate therapy
Industry: Implantable Medical Devices

Partnerships

Seneca Partners (lead investor)University of Manchester collaboration/spin-out origin

Beyond the preview

Go deeper on Gelmetix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gelmetix.

Explore the full profile